Download Files:
LDN193189
$84 – $288
Products Details
Product Description
– LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva[1][2][3].
Web ID
– HY-12071
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C25H22N6
Citations
– Biochim Biophys Acta Gen Subj. 29 October 2021, 130046.|Biomaterials. 2020 May;240:119849.|Cancer Metab. 2023 Jul 13;11(1):9.|Cardiovasc Toxicol. 2019 Jun;19(3):264-275. |EMBO Rep. 2023 Jul 26;e56454.|Eur Respir J. 2021 Dec 2;2100327.|Exp Ther Med. 2019 Apr;17(4):2648-2656. |Front Cell Dev Biol. 13 May 2021.|Front Mol Biosci. 2021 Apr 26;8:663987.|Front Mol Biosci. 2021; 8: 663987.|Int J Mol Sci. 2022, 23(23), 14831.|Int J Ophthalmol. 2022 May 18;15(5):711-720.|iScience. 2019 Sep 27;19:1248-1259.|iScience. 2022 Dec 26;26(1):105898.|J Hazard Mater. 2023 Nov 19, 133028.|J Recept Signal Transduct Res. 2017 Oct;37(5):515-521.|Mar Drugs. 2022 Nov 14;20(11):715.|Mol Cell. 2022 Jun 3;S1097-2765(22)00480-4.|Oxid Med Cell Longev. 2020 Jun 8;2020:4175613.|Patent. US20210346386A1.|Pigment Cell Melanoma Res. 2023 Aug 9.|Research Square Preprint. 2021 Sep.|Research Square Preprint. 2023 May 17.|Sci Rep. 2022 Mar 18;12(1):4740.|Sci Rep. 2022 Mar 25;12(1):5221.|Stem Cell Res Ther. 2022 Aug 19;13(1):424.|Stem Cell Res Ther. 2022 Sep 2;13(1):436.|Stem Cell Res Ther. 2023 Jan 5;14(1):1.|Stem Cells Int. 2022 Apr 28;2022:1560943.|Stem Cells Int. 22 Dec 2022.|Stem Cells. 2023 Apr 8;sxad028.|Transl Oncol. 2019 Dec 19;13(2):125-134|Cancer Lett. 2020 Jan 28;469:390-398.|Cell Rep. 2017 Aug 29;20(9):2227-2237. |Cell Rep. 2017 Aug 29;20(9):2227-2237. |Curr Protoc Cell Biol. 2018 Dec;81(1):e62.|Diabetes. 2020 Apr;69(4):634-646.|EMBO Rep. 2023 Jul 26;e56454.|Harvard Medical School LINCS LIBRARY|Nature. 2022 May;605(7909):325-331.|Patent. US20180263995A1.|Prostate. 2021 Sep 23.|Stem Cell Res Ther. 2021 Jun 11;12(1):345.
References
– [1]Daniel Horbelt, et al. Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation. J Biol Chem. 2015 Feb 6;290(6):3390-404.|[2]Julien Vollaire, et al. The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice. Front Pharmacol. 2019 Jun 19;10:667. |[3]Yu PB, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med, 2008, 14(12), 1363-1369.
CAS Number
– 1062368-24-4
Molecular Weight
– 406.48
Compound Purity
– 99.48
SMILES
– C1(C2=C3N=CC(C4=CC=C(N5CCNCC5)C=C4)=CN3N=C2)=CC=NC6=CC=CC=C16
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 12 mg/mL (ultrasonic;adjust pH to 2 with HCl)|H2O : < 0.1 mg/mL
Target
– TGF-β Receptor
Isoform
– ALK2;ALK3
Pathway
– TGF-beta/Smad
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
